Trial Details

TERMINATED
Basic Information
Clinical ID c4545
Identifier NCT00349752
Trial Title Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease
Trial URL Visit Original Page
Study Information
Study Results

YES

Conditions Crohn's Disease
Interventions BIOLOGICAL: certolizumab pegol 400 mg|OTHER: Placebo
Participant Information
Sponsor UCB Pharma
City Birmingham
Country/Region United States
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type INTERVENTIONAL
Phase PHASE3
Time Information
Start Date 2006-11
Primary Completion Date 2009-07
Completion Date 2009-07